KaloBios Initiates Phase 2 Study with KB001-A Humaneered® Monoclonal Antibody in Cystic Fibrosis Patients

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB001-A, the company’s anti-PcrV Humaneered®, PEGylated monoclonal antibody fragment. The study will investigate the safety and efficacy of intravenously administered KB001-A as a treatment for chronic Pseudomonas aeruginosa (Pa) infection in cystic fibrosis patients. Continue reading KaloBios Initiates Phase 2 Study with KB001-A Humaneered® Monoclonal Antibody in Cystic Fibrosis Patients

Special Webinar on CF Care

Date: Wednesday, December 12th
Time: 2:00 pm – 3:00pm Eastern time
Title: Providing Best Care for Individuals with Cystic Fibrosis: A Partnership with Patients and Families
Speaker: Dr. Michael Boyle, Director of the Adult CF Center at Johns Hopkins Medicine.

Don’t miss this chance to learn about ways to obtain the best care from your healthcare team.  Dr. Boyle is one of the leading CF adult physicians in the United States and is sure to share some helpful information. Continue reading Special Webinar on CF Care

Savara Pharmaceuticals raises $8.6 million for new CF clinical trial

Savara Pharmaceuticals raises $8.6 million for new CF clinical trial of AeroVanc, the first inhaled antibiotic (vancomycin) for the treatment of staph infections in CF. AeroVanc is a dry powder and has the potential to be more effective than intravenous with less side effects. Read the link for more information…

http://www.statesman.com/blogs/content/shared-gen/blogs/austin/startups/entries/2012/06/13/austinbased_savara_pharmaceuti.html